잠시만 기다려 주세요. 로딩중입니다.

The Prognostic Value of the Tumor Shrinkage Rate for Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Receiving Gefitinib

결핵및호흡기질환
2015년 78권 4호 p.315 ~ p.320
박동일 ( Park Dong-Il ) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary

김선영 ( Kim Sun-Young ) - Chungnam National University Hospital Department of Internal Medicine
김주옥 ( Kim Ju-Ock ) - Chungnam National University Hospital Department of Internal Medicine
박희선 ( Park Hee-Sun ) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
문재영 ( Moon Jae-Young ) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
정재욱 ( Chung Chae-Uk ) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary
김성수 ( Kim Song-Soo ) - Chungnam National University Hospital Department of Radiology
서재희 ( Seo Jae-Hee ) - Chungnam National University Hospital Department of Preventive Medicine
이정은 ( Lee Jeong-Eun ) - Chungnam National University Hospital Department of Internal Medicine
정성수 ( Jung Sung-Soo ) - Chungnam National University Hospital Department of Internal Medicine Division of Pulmonary

Abstract

Background : The efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy can be measured based on the rate of treatment response, based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or progression-free survival (PFS). However, there are some patients harboring sensitive EGFR mutations who responded poorly to EGFR-TKI therapy. In addition, there is variability in the PFS after EGFR-TKI treatment.

Materials and Methods : We performed a retrospective analysis of the medical records of 85 patients with non-small cell lung cancer, who had achieved a stable disease or better response at the first evaluation of treatment response, after receiving a 2-month course of gefitinib. We calculated the tumor shrinkage rate (TSR) by measuring the longest and perpendicular diameter of the main mass on computed tomography before, and 2 months after, gefitinib therapy.

Results : There was a significant positive correlation between the TSR and PFS (R=0.373, p=0.010). In addition, a simple linear regression analysis showed that the TSR might be an indicator for the PFS (B±standard error, 244.54±66.79; p=0.001). On univariate analysis, the sex, histologic type, smoking history and the number of prior chemotherapy regimens, were significant prognostic factors. On multivariate regression analysis, both the TSR (β=0.257, p=0.029) and adenocarcinoma (β=0.323, p=0.005) were independent prognostic factors for PFS.

Conclusion : Our results showed that the TSR might be an early prognostic indicator for PFS in patients receiving EGFR-TKI therapy.

키워드

원문 및 링크아웃 정보
 
등재저널 정보
학술진흥재단(KCI) KoreaMed 대한의학회 회원 
주제코드
주제명
(Target field)
연구대상
(Population)
연구참여
(Sample size)
대상성별
(Gender)
질병특성
(Condition Category)
연구환경
(Setting)
연구설계
(Study Design)
연구기간
(Period)
중재방법
(Intervention Type)
중재명칭
(Intervention Name)
키워드
(Keyword)
유효성결과
(Recomendation)
연구비지원
(Fund Source)
근거수준평가
(Evidence Hierarchy)
출판년도
(Year)
참여저자수
(Authors)
대표저자
(1st Authors)
Doi
KCD코드
ICD 03
건강보험코드